H.R. 5811
Referred to CommitteeLong-Term Opioid Efficacy Act of 2018
Introduced 5/15/2018•115th Congress•House
Latest Action
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
6/20/2018 • Senate
Summary
Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
Introduced in House • 5/15/2018
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Drug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsPrescription drugs
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (4)
Party Breakdown
1
Democrats
3
Republicans
0
Independents
Sponsor
R[
Cosponsors (3)
R[
R[
R[
Bill Journey
Originated in the House
Introduced
May 15, 2018
Committee Review
May 17, 2018
Ordered to be Reported (Amended) by Voice Vote.
Floor Debate
June 19, 2018
Passed Chamber
June 19, 2018
Other Chamber
President
Enacted into Law
Text Versions (3)
Referred in Senate6/20/2018
Engrossed in House6/19/2018
Introduced in House5/15/2018